var data={"title":"Aminocaproic acid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminocaproic acid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5612?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminocaproic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminocaproic acid: Patient drug information&quot;</a> and <a href=\"topic.htm?path=aminocaproic-acid-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aminocaproic acid: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133225\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amicar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133261\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifibrinolytic Agent;</li>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Hemostatic Agent;</li>\n      <li>\n        Lysine Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133228\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bleeding:</b> Oral, IV: Loading dose: 4 to 5 g during the first hour, followed by 1 g/hour for 8 hours (or 1.25 g/hour using oral solution) or until bleeding controlled (maximum daily dose: 30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control of bleeding with severe thrombocytopenia (off-label use) (Bartholomew 1989, Gardner 1980):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: 100 mg/kg (maximum dose: 5 g) over 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: Oral, IV: 1 to 4 g every 4 to 8 hours or 1 g/hour (maximum daily dose: 24 g). Additional data may be necessary to further define the role of aminocaproic acid in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control of oral bleeding in congenital and acquired coagulation disorder (off-label use):</b> Oral: 50 to 60 mg/kg every 4 hours (Mannucci 1998). Additional data may be necessary to further define the role of aminocaproic acid in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control of refractory bleeding associated with extracorporeal membrane oxygenation (off-label use): </b>IV: 4 to 5 g loading dose; follow with an infusion of 1 to 1.25 g/hour until bleeding controlled (Buckley 2016). Additional data may be necessary to further define the role of aminocaproic acid in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with thrombolytics (plasminogen-activator) (eg, alteplase, reteplase, tenecteplase) (off-label use): </b>IV: 4 to 5 g (as an alternative to cryoprecipitate); check fibrinogen levels after administration, if fibrinogen &lt;150 mg/dL, cryoprecipitate is recommended (NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of dental procedure bleeding in patients on oral anticoagulant therapy (off-label use):</b> Oral rinse: Hold 4 g/10 mL in mouth for 2 minutes then spit out. Repeat every 6 hours for 2 days after procedure (Souto 1996). Concentration and frequency may vary by institution and product availability. Additional data may be necessary to further define the role of aminocaproic acid in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of perioperative bleeding associated with cardiac surgery (off-label use):</b> IV: Loading dose of 75 to 150 mg/kg (typically 5 to 10 g), followed by 10 to 15 mg/kg/hour (typically 1 g/hour); may add 2 to 2.5 g/L of cardiopulmonary bypass circuit priming solution (Gravlee 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose of 10 g followed by 2 g/hour during surgery; no medication added to the bypass circuit (Fergusson 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 g over 20 to 30 minutes prior to skin incision, followed by 10 g after heparin administration then 10 g at discontinuation of cardiopulmonary bypass (Vander Salm1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subarachnoid hemorrhage (off-label use):</b> IV: Loading dose of 4 g followed by 1 g/hour infusion for up to 72 hours after SAH onset. <b>Note:</b> Discontinue infusion 4 hours prior to angiography or 2 hours prior to endovascular ablation of aneurysm (Diringer 2011; Starke 2008). Additional data may be necessary to further define the role of aminocaproic acid in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traumatic hyphema (off-label use):</b> Oral: 50 mg/kg/dose every 4 hours (maximum daily dose: 30 g) for 5 days (Brandt 2001; Crouch 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133246\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=aminocaproic-acid-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aminocaproic acid: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prevention of perioperative bleeding associated with cardiac surgery (off-label use):</b> IV: 100 mg/kg given over 20-30 minutes after induction and prior to incision, 100 mg/kg during cardiopulmonary bypass, and 100 mg/kg after heparin reversal over 3 hours (Chauhan, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO) (off-label use):</b> IV: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours (Downard, 2003; Horwitz, 1998; Wilson, 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis) (off-label use):</b> Children and Adolescents: IV: 100 mg/kg given over 15-20 minutes after induction, followed by 10 mg/kg/hour for the remainder of the surgery; discontinue at time of wound closure (Florentino-Pineda, 2001; Florentino-Pineda, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Traumatic hyphema (off-label use):</b> Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133229\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133230\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">May accumulate in patients with decreased renal function. When used during cardiopulmonary bypass in anephric patients, a normal or slightly reduced loading dose and a continuous infusion rate of 5 mg/kg/hour has been recommended (Gravlee, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671610\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133202\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 25% (236.5 mL) [contains edetate disodium, methylparaben, propylparaben, saccharin sodium; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 25% (473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25% (237 mL [DSC], 473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 1000 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg [DSC], 1000 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133205\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May administer loading dose over 15-60 minutes depending on indication; a continuous infusion may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471315\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 5000 mg in 250 mL (concentration: 20 mg/mL) of D5W, NS, or Ringer's injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133204\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis)   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720677\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bleeding associated with dental procedures in patients on oral anticoagulant therapy (mouth rinse); Bleeding (control) in severe thrombocytopenia; Bleeding (prevention) associated with extracorporeal membrane oxygenation (infants/children/adolescents); Control of refractory bleeding associated with extracorporeal membrane oxygenation; Intracranial hemorrhage associated with thrombolytics (plasminogen-activator) (eg, alteplase, reteplase, or tenecteplase); Oral bleeding (control) in congenital and acquired coagulation disorders; Perioperative bleeding (prevention) associated with cardiac surgery; Perioperative bleeding (prevention) associated with spinal surgery (eg, idiopathic scoliosis); Subarachnoid hemorrhage; Traumatic hyphema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133270\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amicar may be confused with amikacin, Amikin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar [US] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133193\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash, pruritus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dry ejaculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site necrosis, injection site pain, injection site reactions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Vision decreased, watery eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, nasal congestion, pulmonary embolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Hepatic lesion, hyperkalemia, myocardial lesion </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133208\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intrarenal obstruction: May occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skeletal muscle weakness: Ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use. Monitor CPK; discontinue treatment with a rise in CPK.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may accumulate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood products: Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Do not administer without a definite diagnosis of laboratory findings indicative of hyperfibrinolysis. Inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of DIC. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IV administration: Avoid rapid IV administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298735\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133195\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8561&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-inhibitor Coagulant Complex (Human): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor IX Complex (Human) [(Factors II, IX, X)]: Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, use of this combination may increase the risk of thrombosis. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133198\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133211\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520941\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if aminocaproic acid is excreted in breast milk. The manufacturer recommends that caution be exercised when administering aminocaproic acid  to nursing women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133200\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fibrinogen, fibrin split products, creatine phosphokinase (with long-term therapy), BUN, creatinine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds competitively to plasminogen; blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin, resulting in inhibition of fibrin degradation (fibrinolysis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133207\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~1 to 72 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely through intravascular and extravascular compartments; V<sub>d</sub>: Oral: 23 L;  IV: 30 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1.2 &plusmn; 0.45 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (65% as unchanged drug, 11% as metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133210\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amicar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 g/mL (236.5 mL): $2,890.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminocaproic Acid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/mL (20 mL): $7.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amicar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $732.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (30): $1,465.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038523\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acepramin (HN, HU);</li>\n      <li>Acidum e-aminocapronicum (PL);</li>\n      <li>AKK (UA);</li>\n      <li>Amicar (AE, AU, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Caproamin (VE);</li>\n      <li>Caprolest (NL);</li>\n      <li>Caprolex (BD);</li>\n      <li>Caprolisin (IT);</li>\n      <li>Darnitsa (UA);</li>\n      <li>EAC (DE);</li>\n      <li>Epsamon (CH);</li>\n      <li>Epsicaprom (PT);</li>\n      <li>Epsikapron (QA, SA);</li>\n      <li>Epsilon (FI);</li>\n      <li>Hamostat (IN);</li>\n      <li>Hemolysin (BD);</li>\n      <li>Hexalense (FR);</li>\n      <li>Inselon (TW);</li>\n      <li>Ipron (TW);</li>\n      <li>Ipsilon (AR, BR, JP, PY, UY);</li>\n      <li>Kai Nai Yin (CN);</li>\n      <li>Kaposelin (UA);</li>\n      <li>Minocap (BD);</li>\n      <li>Plaslloid (TW);</li>\n      <li>Resplamin (JP);</li>\n      <li>Syrop acidi e-aminocapronici (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Banerjee A, Stoica C, and Walia A, &quot;Acute Hyperkalemia as a Complication of Intravenous Therapy With Epsilon-Aminocaproic Acid,&quot; <i>J Clin Anesth</i>, 2011, 23(7):565-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22050802/pubmed\" target=\"_blank\" id=\"22050802\">22050802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2774776\"></a>Bartholomew JR, Salgia R, and Bell WR, &ldquo;Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid,&rdquo; <i>Arch Intern Med</i>, 1989, 149(9):1959-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2774776/pubmed\" target=\"_blank\" id=\"2774776\">2774776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11732035\"></a>Brandt MT and Haug RH, &quot;Traumatic Hyphema: A Comprehensive Review,&quot; <i>J Oral Maxillofac Surg</i>, 2001, 59(12):1462-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11732035/pubmed\" target=\"_blank\" id=\"11732035\">11732035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26907195\"></a>Buckley LF, Reardon DP, Camp PC, et al. Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: four adult case reports and a review of the literature. <i>Heart Lung</i>. 2016;45(3):232-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/26907195/pubmed\" target=\"_blank\" id=\"26907195\">26907195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casati V, Guzzon D, Oppizzi M, et al, &ldquo;Hemostatic Effects of Aprotinin, Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Cardiac Surgery,&rdquo; <i>Ann Thorac Surg</i>, 1999, 68(6):2252-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/10617012/pubmed\" target=\"_blank\" id=\"10617012\">10617012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15073700\"></a>Chauhan S, Das SN, Bisoi A, et al, &ldquo;Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,&rdquo; <i>J Cardiothorac Vasc Anesth</i>, 2004, 18(2):141-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/15073700/pubmed\" target=\"_blank\" id=\"15073700\">15073700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10505828\"></a>Crouch ER Jr and Crouch ER, &quot;Management of Traumatic Hyphema: Therapeutic Options,&quot; <i>J Pediatr Ophthalmol Strabismus</i>, 1999, 36(5):238-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/10505828/pubmed\" target=\"_blank\" id=\"10505828\">10505828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9298049\"></a>Crouch ER Jr, Williams PB, Gray MK, et al, &ldquo;Topical Aminocaproic Acid in the Treatment of Traumatic Hyphema,&rdquo; <i>Arch Ophthalmol</i>, 1997, 115(9):1106-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9298049/pubmed\" target=\"_blank\" id=\"9298049\">9298049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daily PO, Lamphere JA, Dembitsky WP, et al, &ldquo;Effect of Prophylactic Epsilon-Aminocaproic Acid on Blood Loss and Transfusion Requirements in Patients Undergoing First-time Coronary Artery Bypass Grafting: A Randomized, Pprospective, Double-Blind Study,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 1994, 108(1):99-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8028387/pubmed\" target=\"_blank\" id=\"8028387\">8028387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Peppo A, Pierri MD, Scafuri A, et al, &ldquo;Intraoperative Antifibrinolysis and Blood-Saving Techniques in Cardiac Surgery: Prospective Trial of 3 Antifibrinolytic Drugs,&rdquo; <i>Tex Heart Inst J</i>, 1995, 22(3):231-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/7580360/pubmed\" target=\"_blank\" id=\"7580360\">7580360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diringer MN, Bleck TP, Hemphill JC 3rd, et al; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. <i>Neurocrit Care</i>. 2011;15(2):211-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/21773873/pubmed\" target=\"_blank\" id=\"21773873\">21773873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12891495\"></a>Downard CD, Betit P, Chang RW, et al, &quot;Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review,&quot; <i>J Pediatr Surg</i>, 2003, 38(8):1212-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12891495/pubmed\" target=\"_blank\" id=\"12891495\">12891495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eaton MP, &ldquo;Antifibrinolytic Therapy in Surgery for Congenital Heart Disease,&rdquo; <i>Anest Analg</i>, 2008, 106(4):1087-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18349177/pubmed\" target=\"_blank\" id=\"18349177\">18349177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eberle B, Mayer E, Hafner G, et al, &ldquo;High-Dose Epsilon-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations,&rdquo; <i>Ann Thorac Surg</i>, 1998, 65(3):667-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9527193/pubmed\" target=\"_blank\" id=\"9527193\">9527193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18480196\"></a>Fergusson DA, Hebert PC, Mazer CD, et al, &ldquo;A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery,&rdquo; <i>N Engl J Med</i>, 2008, 358(22):2319-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18480196/pubmed\" target=\"_blank\" id=\"18480196\">18480196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11413428\"></a>Florentino-Pineda I, Blakemore LC, Thompson GH, et al, &quot;The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study,&quot; <i>Spine (Phila Pa 1976)</i>, 2001, 26(10):1147-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11413428/pubmed\" target=\"_blank\" id=\"11413428\">11413428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14752343\"></a>Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, &quot;The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study,&quot; <i>Spine (Phila Pa 1976)</i>, 2004, 29(3):233-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/14752343/pubmed\" target=\"_blank\" id=\"14752343\">14752343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26714677\"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6965311\"></a>Gardner FH and Helmer RE 3rd, &ldquo;Aminocaproic Acid. Use in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia,&rdquo; <i>JAMA</i>, 1980, 243(1):35-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6965311/pubmed\" target=\"_blank\" id=\"6965311\">6965311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gravlee GP and Spiess B, &quot;Pharmacologic Prophylaxis for Post-Cardiopulmonary Bypass Bleeding,&quot; <i>Cardiopulmonary Bypass: Principles and Practice</i>, 3rd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2008, 522-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haut MT, Mauro VF, and Davis HH, &ldquo;Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations,&rdquo; <i>DICP</i>, 1989, 23(11):922-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2596137/pubmed\" target=\"_blank\" id=\"2596137\">2596137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9856877\"></a>Horwitz JR, Cofer BR, Warner BW, et al, &quot;A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO,&quot; <i>J Pediatr Surg</i>, 1998, 33(11):1610-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9856877/pubmed\" target=\"_blank\" id=\"9856877\">9856877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kikura M, Levy JH, Tanaka KA, et al, &ldquo;A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting Surgery,&rdquo; <i>J Am Coll Surg</i>, 2006, 202(2):216-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/16427545/pubmed\" target=\"_blank\" id=\"16427545\">16427545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6782532\"></a>Lucas ON and Albert TW, &ldquo;Epsilon Aminocaproic Acid in Hemophiliacs Undergoing Dental Extractions: A Concise Review,&rdquo; <i>Oral Surg Oral Med Oral Pathol</i>, 1981, 51(2):115-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6782532/pubmed\" target=\"_blank\" id=\"6782532\">6782532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9673304\"></a>Mannucci P, &ldquo;Hemostatic Drugs,&rdquo; <i>N Engl J Med</i>, 1998, 339(4):245-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9673304/pubmed\" target=\"_blank\" id=\"9673304\">9673304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6870623\"></a>McGetrick JJ, Jampol LM, Goldberg MP, et al, &ldquo;Aminocaproic Acid Decreases Secondary Hemorrhage After Traumatic Hyphema,&rdquo; <i>Arch Ophthalmol</i>, 1983, 101(7):1031-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6870623/pubmed\" target=\"_blank\" id=\"6870623\">6870623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nzerue CM and Falana B, &quot;Refractory Hyperkalaemia Associated With Use of Epsilon-Aminocaproic Acid During Coronary Bypass in a Dialysis Patient,&quot; <i>Nephrol Dial Transplant</i>, 2002, 17(6):1150-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12032221/pubmed\" target=\"_blank\" id=\"12032221\">12032221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patatanian E and Fugate SE,, &ldquo;Hemostatic Mouthwashes in Anticoagulated Patients Undergoing Dental Extraction,&rdquo; <i>Ann Pharmacother</i>, 2006, 40(12):2205-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/17090725/pubmed\" target=\"_blank\" id=\"17090725\">17090725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7580360\"></a>Penta de Peppo A1, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. <i>Tex Heart Inst J</i>. 1995;22(3):231-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/7580360/pubmed\" target=\"_blank\" id=\"7580360\">7580360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieramici DJ, Goldberg MF, Melia M, et al, &ldquo;A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial of Topical Aminocaproic Acid (Caprogel) in the Management of Traumatic Hyphema,&rdquo; <i>Ophthalmology</i>, 2003, 110(11):2106-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/14597516/pubmed\" target=\"_blank\" id=\"14597516\">14597516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinosky ML, Kennedy DJ, Fishman RL, et al, &ldquo;Tranexamic Acid Reduces Bleeding After Cardiopulmonary Bypass When Compared to Epsilon Aminocaproic Acid and Placebo,&rdquo; <i>J Card Surg</i>, 1997, 12(5):330-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9635271/pubmed\" target=\"_blank\" id=\"9635271\">9635271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sane DC, Califf RM, Topol EJ, et al, &quot; Bleeding During Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management,&quot; <i>Ann Intern Med</i>, 1989, 111(12):1010-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2688504/pubmed\" target=\"_blank\" id=\"2688504\">2688504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8530996\"></a>Souto JC, Olover A, Zuazu-Jausoro I, et al, &ldquo;Oral Surgery in Anticoagulated Patients Without Reducing the Dose of Oral Anticoagulant: A Prospective Randomized Study,&rdquo; <i>J Oral Maxillofac Surg</i>, 1996, 54(1):27-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8530996/pubmed\" target=\"_blank\" id=\"8530996\">8530996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. <i>Stroke</i>. 2008;39(9):2617-2621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18658042/pubmed\" target=\"_blank\" id=\"18658042\">18658042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teboul BK, Jacob JL, Barsoum-Homsy M, et al, &ldquo;Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,&rdquo; <i>Ophthalmology</i>, 1995, 102(11):1646-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9098257/pubmed\" target=\"_blank\" id=\"9098257\">9098257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8873738\"></a>Vander Salm TJ, Kaur S, Lancey RA, et al, &ldquo;Reduction of Bleeding After Heart Operations Through the Prophylactic Use of Epsilon-Aminocaproic Acid,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 1996, 112(4):1098-107<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8873738/pubmed\" target=\"_blank\" id=\"8873738\">8873738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walton W, Von Hagen S, Grigorian R, et al, &ldquo;Management of Traumatic Hyphema,&rdquo; <i>Surv Ophthalmol</i>, 2002, 47(4):297-334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12161209/pubmed\" target=\"_blank\" id=\"12161209\">12161209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8483066\"></a>Wilson JM, Bower LK, Fackler JC, et al, &quot;Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO,&quot; <i>J Pediatr Surg</i>, 1993, 28(4):536-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8483066/pubmed\" target=\"_blank\" id=\"8483066\">8483066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang YP and Trissel LA, &ldquo;Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection,&rdquo; <i>Int J Pharm Compound</i>, 1997, 1(2):132-4.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8561 Version 136.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F133225\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F133261\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F133228\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F133246\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F133229\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F133230\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671610\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133202\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F133186\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F133205\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471315\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F133204\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720677\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133270\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133193\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133208\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298735\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133195\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F133198\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133211\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20520941\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F133200\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F133207\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133210\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038523\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8561|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminocaproic-acid-patient-drug-information\" class=\"drug drug_patient\">Aminocaproic acid: Patient drug information</a></li><li><a href=\"topic.htm?path=aminocaproic-acid-pediatric-drug-information\" class=\"drug drug_pediatric\">Aminocaproic acid: Pediatric drug information</a></li></ul></div></div>","javascript":null}